Home / Business and Economy / Dr. Reddy's Obeda: India's New Semaglutide Injection Arrives
Dr. Reddy's Obeda: India's New Semaglutide Injection Arrives
25 Feb
Summary
- Dr. Reddy's plans to launch generic semaglutide, Obeda, in March.
- The injection offers a potential 60% cost reduction from branded versions.
- India faces a growing diabetes and obesity epidemic, increasing demand.
Dr. Reddy's Laboratories is preparing to introduce a generic version of semaglutide in India, with a launch anticipated in March under the brand name Obeda. This development comes as Indian pharmaceutical companies gear up for the expiry of patent protection for semaglutide in March 2026. The active ingredient in Novo Nordisk's blockbuster diabetes and weight-loss drugs, semaglutide, will become more accessible.
Dr. Reddy's has initiated trademark applications for the Obeda brand. The company plans to offer the injectable pens at a competitive price, potentially up to 60% lower than current market rates. This initiative aligns with the growing health challenges in India, which has a high number of adults with diabetes and a projected increase in overweight and obese populations by 2050.
The company has already secured regulatory approval for manufacturing and selling a generic Ozempic and is awaiting clearance for a generic Wegovy. The introduction of affordable semaglutide options is expected to intensify market competition, as other pharmaceutical giants like Novo Nordisk and Eli Lilly have also established their presence in India with their respective diabetes and weight-loss drugs.
